Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim to collaborate on multiple myeloma drug

Boehringer Ingelheim to collaborate on multiple myeloma drug

6th May 2010

Boehringer Ingelheim is to enter into partnership with cancer antibody specialist Micromet in order to develop a new treatment for multiple myeloma.

The two firms’ collaboration will be centred on a BiTE antibody developed by Micromet, with Boehringer Ingelheim to take responsibility for manufacturing clinical development and co-commercialisation.

This agreement will also see Micromet earn up to 50 million euros (42.5 million pounds) in milestone payments and royalties, depending on the clinical progress and market success of the resulting drug.

It is hoped that the therapy will provide a new breakthrough in the treatment of a disease which is currently incurable.

Dr Wolfgang Rettig, head of corporate research at Boehringer Ingelheim, said: “We believe that a BiTE antibody has the potential to address the significant unmet medical need of patients with multiple myeloma.”

Last month, Boehringer Ingelheim published its financial report for the first quarter of the year, reporting a 9.7 per cent net sales increase compared to the corresponding period of 2009.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.